GPS Announcement:
We are excited to announce the abstract presented by Duke at AUA 2024 is now available: “Utilizing the Genomic Prostate Score (GPS) as a Prognostic Biomarker in Patients with Localized Prostate Cancer undergoing Focal Therapy.”
Link to abstract: https://www.auajournals.org/doi/10.1097/01.JU.0001008692.26556.39.12
Key Takeaways:
- The study is a retrospective review of patients with localized prostate cancer treated with focal therapy between 2005 and 2022 at Duke University.
- The GPS appears to be a prognostic indicator of time to failure-free survival and biopsy recurrence (>GG2) in men with low-risk (24%), intermediate-risk (68%), and high-risk (9%) undergoing focal therapy.
- Overall Failure-Free survival at 5 years was 86%.
- PI: Thomas Polacik, MD – Duke Cancer Institute and VA Medical Center in Durham, North Carolina
Summary
The study was an institutional review board-approved retrospective review of 81 prostate cancer patients undergoing focal therapy between 2005 and 2022 at Duke University. The study evaluated the association between GPS results and failure-free survival, defined as the requirement of salvage therapy, including RP, RT, whole gland ablation, systemic therapy, development of metastasis, and prostate cancer death. The authors also evaluated whether the GPS result can predict > GG2 biopsy recurrence following focal ablation. The study included men with localized disease, GGG 2-5 or high volume GGG1 (max tumor length > 6mm), and < T2cN0M0. The study demonstrated that GPS was a prognostic indicator of failure-free survival, in-field and out-field biopsy recurrence (> GG2) post-focal therapy.
